Gapping down
In reaction to disappointing earnings/guidance:
- OMI -14.4% (also names Edward Pesicka Pres/CEO effective March 4; lowers dividend), WIX -9.3%, HCKT -7.5%, LC -6.1%, CVS -6%, CXO -5.8%, TILE -4.2%, WWW -3.8%, TVTY -3.5%, I -3.2%, VPG -2.5%, TXRH -2.4%, FANG -2.3%, GEL -2.2%, VRSK -1.6%, AJRD -0.9%
Other news:
- OVID -15.2% (commences offering of its common stock and Series A convertible preferred stock)
- AI -4.6% (prices 6 mln shares of common stock worth gross proceeds of $50.0 mln)
- LUV -4% (comments on Q1 operating revenue trends, has continued to experience softness in passenger demand and bookings as a result of the government shutdown; lowers RASM guidance)
- NRZ -3.1% (prices underwritten public offering of 40,297,096 shares of its common stock)
- ARR -2.9% (prices underwritten public offering of 7,200,000 shares of common stock at a public offering price of $20.33 per share)
- CPT -1.3% (announces public offering of 3,375,000 common shares)
- MRK -1.3% (Merck announces pivotal Phase 3 KEYNOTE-240 trial evaluating KEYTRUDA did not meet co-primary endpoints of overall survival and progression-free survival)
Analyst comments:
- SCHW -2.9% (downgraded to Sell from Neutral at UBS)
- PSTG -2.7% (downgraded to Mkt Perform from Outperform at Raymond James)
- TTD -2.4% (downgraded to Hold from Buy at Stifel)
- CTL -1.5% (downgraded to Sector Perform from Outperform at RBC Capital Mkts)
- ETFC -1.5% (downgraded to Neutral from Buy at UBS)
- ALLE -1.3% (downgraded to Neutral from Buy at Goldman)
- TEVA -1.2% (downgraded to Neutral from Buy at Mizuho)
- PANW -1% (downgraded to Hold from Buy at Gabelli & Co)
- ECL -0.7% (downgraded to Neutral from Overweight at JP Morgan)